Walleye Capital LLC Cuts Position in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Walleye Capital LLC has reduced its holdings in BioCryst Pharmaceuticals by 56.6% in the first quarter, now owning 154,692 shares valued at $1.16 million.
• BioCryst Pharmaceuticals reported a 49.5% increase in revenue year-over-year, totaling $163.35 million, while also exceeding EPS estimates by $0.12.
• Analyst ratings for BioCryst vary, with Barclays setting a new price target of $11.00, while Needham maintains a "buy" rating with a target of $17.00, reflecting strong investor interest.

Walleye Capital LLC lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 56.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 154,692 shares of the biotechnology company's stock after selling 201,830 shares during the quarter. Walleye Capital LLC owned 0.07% of BioCryst Pharmaceuticals worth $1,160,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter worth about $80,000. Mariner LLC raised its position in BioCryst Pharmaceuticals by 32.1% in the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 3,224 shares during the period. MetLife Investment Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 6.0% during the 4th quarter. MetLife Investment Management LLC now owns 126,949 shares of the biotechnology company's stock worth $955,000 after acquiring an additional 7,199 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in BioCryst Pharmaceuticals by 84.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 23,083 shares of the biotechnology company's stock valued at $174,000 after purchasing an additional 10,583 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in shares of BioCryst Pharmaceuticals by 33.9% in the fourth quarter. Hsbc Holdings PLC now owns 90,061 shares of the biotechnology company's stock worth $677,000 after purchasing an additional 22,814 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Bank of America lifted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. Needham & Company LLC reiterated a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Finally, Wedbush raised their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, June 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Trading Down 0.4%

Shares of BCRX stock traded down $0.04 on Thursday, reaching $8.26. 800,590 shares of the company's stock were exchanged, compared to its average volume of 3,713,534. The company's fifty day simple moving average is $8.57 and its 200 day simple moving average is $8.77. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.01 and a 52 week high of $11.31. The stock has a market capitalization of $1.73 billion, a PE ratio of -45.86, a P/E/G ratio of 1.89 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The firm's revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.06) earnings per share. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.10% of the stock is owned by company insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.